Late diagnosis of agammaglobulinemia in an 8-year-old boy
Pediatria i Medycyna Rodzinna, 2016 Chromosome X-linked Bruton agammaglobulinemia is classified as a primary immunodeficiency disorder. It is a genetic condition associated with a mutation in the BTK gene encoding tyrosine kinase.
Małgorzata Sopińska +4 more
doaj +1 more source
X-Linked Agammaglobulinemia A Clinical and Molecular Analysis
Medicine, 1996 X-linked agammaglobulinemia (XLA), characterized by a profound deficiency of B lymphocytes due to an arrest in B lymphocyte development, is caused by mutations in the gene encoding Btk (Bruton tyrosine kinase). The BTK gene has been cloned and the genomic organization determined.
Hans D. Ochs, C. I. E. Smith
openaire +3 more sources
Journal of Microbiology, Immunology and Infection, 2020 X-linked agammaglobulinemia (XLA) is a primary immunodeficiency disease. We reported two 7-month-old identical male twins with Pseudomonas aeruginosa sepsis who initially manifested as oral ecthyma gangrenosum and were finally diagnosed to have XLA.
Sheng-Chieh Lin +4 more
doaj +1 more source
A propósito del artículo: Actualización sobre las bases genéticas y perspectivas terapéuticas en la Agammaglobulinemia ligada al X o enfermedad de Bruton [PDF]
Regarding the article: Update on the genetic bases and therapeutic perspectives in X-linked Agammaglobulinemia or Bruton´s diseaseA propósito del artículo: Actualización sobre las bases genéticas y perspectivas terapéuticas en la Agammaglobulinemia ...
Taboada-Lugo, Noel
core +1 more source
X-linked agammaglobulinemia and isolated growth hormone deficiency
The Turkish Journal of Pediatrics, 1998 X-linked agammaglobulinemia and isolated growth hormone deficiency was first described in 1980 and then classified as a different primary immune deficiency.
D Arslan +3 more
doaj
Chapter Three. EED library as a basis for systematic reviews [PDF]
, 2016 3.1 Defining Systematic Review Question Priorities 3.2 Determining Relevance to the Systematic Review 3.3 Acquisition of References and Copyright Fair Use Compliance 3.4 Documenting Relevance to the Systematic Review 3.5 Data Extraction for the ...
Denno, Donna M +4 more
core +1 more source
Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML [PDF]
, 2014 Pharmacological targeting of BTK using ibrutinib has recently shown encouraging clinical activity in a range of lymphoid malignancies. Recently we reported that ibrutinib inhibits human acute myeloid leukemia (AML) blast proliferation and leukemic cell ...
Bowles, Kristian M +6 more
core +2 more sources
Neutropenia Associated with X-Linked Agammaglobulinemia
Iranian Journal of Allergy, Asthma and Immunology, 2009 X-linked Agammaglobulinemia (XLA) is a hereditary immunodeficiency, characterized by an early onset of recurrent bacterial infections, hypogammaglobulinemia and markedly reduced B lymphocytes number.
Aghamohammadi Asghar +9 more
doaj
Long-term efficacy and safety of Hizentra® in patients with primary immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials [PDF]
, 2018 Many patients with primary immunodeficiency (PID) require immunoglobulin G (IgG) replacement therapy, delivered as intravenous IgG (IVIG) or subcutaneous IgG (SCIG). We aim to identify trends in efficacy and safety that would not be evident in individual
Borte, Michael +8 more
core +2 more sources
X-Linked Agammaglobulinemia Presenting with Secondary Hemophagocytic Syndrome: A Case Report
Case Reports in Medicine, 2013 Introduction. Coincidence of X-linked agammaglobulinemia (XLA) and secondary hemophagocytic syndrome (sHS) is atypical. Both diseases are rare and pathogenesis of the latter one is not clearly known. Case Presentation. A 5-year-old boy was diagnosed both
Can Ozturk +3 more
doaj +1 more source